EGFR and non-small cell lung carcinoma: Erlotinib (Tarceva®) is an oral anticancer agent, which is registered for the second- and third-line treatment of NSCLC since 2006 [31] Erlotinib is a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR-TKI).